Simmitinib
- Generic Name
- Simmitinib
A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma
Phase 3
Not yet recruiting
- Conditions
- Advanced Oesophageal Squamous Cell Carcinoma
- Interventions
- Drug: investigator's choice of chemotherapy,include docetaxel or irinotecan.
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Shanghai Runshi Pharmaceutical Technology Co., Ltd
- Target Recruit Count
- 450
- Registration Number
- NCT06656091
A Study of Simmitinib Plus SG001 in Advanced Solid Tumors
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Shanghai Runshi Pharmaceutical Technology Co., Ltd
- Target Recruit Count
- 168
- Registration Number
- NCT06132217
- Locations
- 🇨🇳
Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
A Phase I Trial of Simmitinib in Advanced Solid Tumors
- First Posted Date
- 2019-08-15
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT04058587
- Locations
- 🇨🇳
CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath